Trevi Therapeutics (TRVI) PT Raised to $18 at Stifel: Haduvio Development up in 2026
Tweet Send to a Friend
Stifel analyst Annabel Samimy raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $18.00 (from $15.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
